Testing a treatment to restore UNC13A function in ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosis of ALS that started within the last 2 years.
- You need to be able to perform breathing tests and have a breathing capacity of at least 60% of what is expected for your age and height.
- You must be willing to travel to the study site, undergo MRI scans, spinal taps, and blood draws.
- You should not have a SOD1 or FUS gene mutation, and cannot have had gene therapy, stem cell therapy, or certain other experimental treatments before.
- You must be on a stable dose of your current ALS medication for at least 4 weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.